- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07926490
Risk Factors for Postoperative Outcomes and Complications in Patients With Large Intrathoracic Tumors: A Multicenter Analysis
Risk Factors for Outcomes and Postoperative Complications in Patients with Large Intrathoracic Neoplasms (GIANTOR) What is the purpose of this study? The main goal of this study is to evaluate the results of surgery for removing very large tumors inside the chest. While common lung cancers are well-studied, other types of chest tumors (like solitary fibrous tumors or nerve-related tumors) can grow slowly and reach a massive size (over 5 cm) before they are found. Because these cases are rare, there is little data on the best way to operate on them. Researchers want to identify the risks and complications associated with these surgeries to improve patient care.
Why is this study important? Operating on large chest tumors is technically difficult because they often press against or grow into nearby vital organs. Currently, doctors mostly rely on reports of single cases rather than large groups of patients. This study will look at a large multicenter group to provide more reliable information on surgical techniques (such as open surgery vs. minimally invasive) and long-term recovery.
Who can participate in this study? The study includes patients who meet the following criteria:Adults aged 18 years or older.Patients with intrathoracic tumors measuring 5 cm or larger.Tumors that can be either benign (non-cancerous) or malignant (cancerous).Patients who underwent surgery with the intent to completely remove the tumor.The study excludes patients with common non-small cell lung cancer (NSCLC), thymomas, or sarcomas of the chest wall.
How is the study designed? This is a multicenter, retrospective and prospective cohort study. It is led by the IRCCS Azienda Ospedaliero-Universitaria di Bologna and involves six other major thoracic surgery centers in Italy (Rome, Padua, Turin, Pisa, and Milan).Researchers will review medical records of approximately 400 patients who had surgery between January 2005 and December 2024. Data will be collected on:Surgical complications during and after the operation.The type of surgical access used.Patient survival and disease recurrence.
What are the expected outcomes? Researchers hope to:Determine the rate of complications and deaths related to the surgery.Find specific risk factors (like patient health or tumor size) that lead to more complications.Compare different surgical methods to see which works best for large tumors.Measure long-term survival and how long patients stay free of disease after surgery.The results will be shared through scientific journals and international conferences to help surgeons worldwide manage these complex cases more safely.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Pietro Bertoglio, MD
- Telefonní číslo: 0516478362
- E-mail: pietro.bertoglio@aosp.bo.it
Studijní místa
-
-
Bologna
-
Bologna, Bologna, Itálie, 40138
- Nábor
- IRCSS Azienda Ospedaliero-Universitaria di Bologna
-
Kontakt:
- Pietro Bertoglio, MD
- Telefonní číslo: 0516478362
- E-mail: pietro.bertoglio@aosp.bo.it
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
The study population consists of patients who underwent surgery for large intrathoracic tumors at the participating centers between January 2005 and December 2024. Subjects will be identified through a review of medical records, surgical registries, and outpatient documentation available at the participating facilities, and enrollment will take place during scheduled outpatient follow-up visits or via telephone contact made during postoperative follow-up, in accordance with the standard care pathway. In both cases, patient selection will be conducted in accordance with the inclusion and exclusion criteria established in the protocol, following verification of the available clinical documentation.
Popis
Inclusion Criteria:
- Age ≥ 18 years
- Intrathoracic tumors ≥ 5 cm in size
- Tumors with either benign or malignant histology
- Tumors treated surgically with the aim of complete resection
Exclusion Criteria:
- NSCLC
- Thymomas
- Wall sarcomas
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: RETROSPECTIVE
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Intraoperative complication rate, postoperative complication rate
Časové okno: baseline
|
baseline
|
|
Relationship between the development of complications and the presence of pre- or intraoperative risk factors
Časové okno: baseline
|
baseline
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Perioperative mortality rate
Časové okno: baseline
|
baseline
|
|
Rate of surgical approach utilization
Časové okno: baseline
|
baseline
|
|
Overall Survival and Disease-Free Survival
Časové okno: baseline
|
baseline
|
|
association of surgical approach utilization with postoperative complications
Časové okno: baseline
|
baseline
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- GIANTOR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .